Tomoki Ochiai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomoki Ochiai has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
Shigeru Saito
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
27 shared publicationsShingo Mizuno
Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Kamakura, Japan
21 shared publicationsKazuki Tobita
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
19 shared publicationsYutaka Tanaka
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
19 shared publicationsFutoshi Yamanaka
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
18 shared publicationsKoki Shishido
Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan
18 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 41 (3) , 749-760
Geometric coronary constraints and anatomical feasibility of redo TAVR in Asian patients with Evolut valves: A CT-based simulation study
Redo transcatheter aortic valve replacement (TAVR) when implanting a second transcatheter valve within a tall-frame self-expanding valve can be challenging because of unfavorable coronary-related anatomy. However, computed tomography (CT)-based data in Asian patients with smaller aortic root dimensions remain limited.This study aimed to evaluate the CT-based geometric coronary constraints by simulating implantation of a balloon-expandable SAPIEN 3 (S3) within a previously implanted self-expanding Evolut valve in Asian patients. Consecutive patients who underwent TAVR using Evolut at a single center between May 2021 and May 2023 and had post-procedural CT were analyzed. Virtual S3-in-Evolut implantation was simulated at three depths (node 4: low; node 5: intermediate; node 6: high). Geometric coronary constraint was assessed based on the relationship between the neo-skirt plane and coronary ostia and the valve-to-aorta distance. Among 113 patients, the distribution of geometric coronary constraint differed by simulated S3 implantation depth. With high S3 implantation (node 6), severe, intermediate, and low constraint were observed in 63.7%, 23.9%, and 12.4% of patients, respectively; with intermediate implantation (node 5), in 31.0%, 29.2%, and 39.8%; and with low implantation (node 4), in 3.5%, 16.8%, and 79.6%. In multivariable analysis, smaller sino-tubular junction diameter was independently associated with severe geometric coronary constraint.Geometric coronary constraints that may affect coronary access after redo TAVR with S3-in-Evolut configurations depend on the implantation depth of both the index Evolut and the simulated S3. However, the hemodynamic significance and clinical impact of these geometric findings require validation through flow studies. Graphical Abstract The alternative text for this image may have been generated using AI.
- 13 May 2026
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 41 (3) , 749-760
Open AccessGeometric coronary constraints and anatomical feasibility of redo TAVR in Asian patients with Evolut valves: A CT-based simulation study
Redo transcatheter aortic valve replacement (TAVR) when implanting a second transcatheter valve within a tall-frame self-expanding valve can be challenging because of unfavorable coronary-related anatomy. However, computed tomography (CT)-based data in Asian patients with smaller aortic root dimensions remain limited.This study aimed to evaluate the CT-based geometric coronary constraints by simulating implantation of a balloon-expandable SAPIEN 3 (S3) within a previously implanted self-expanding Evolut valve in Asian patients. Consecutive patients who underwent TAVR using Evolut at a single center between May 2021 and May 2023 and had post-procedural CT were analyzed. Virtual S3-in-Evolut implantation was simulated at three depths (node 4: low; node 5: intermediate; node 6: high). Geometric coronary constraint was assessed based on the relationship between the neo-skirt plane and coronary ostia and the valve-to-aorta distance. Among 113 patients, the distribution of geometric coronary constraint differed by simulated S3 implantation depth. With high S3 implantation (node 6), severe, intermediate, and low constraint were observed in 63.7%, 23.9%, and 12.4% of patients, respectively; with intermediate implantation (node 5), in 31.0%, 29.2%, and 39.8%; and with low implantation (node 4), in 3.5%, 16.8%, and 79.6%. In multivariable analysis, smaller sino-tubular junction diameter was independently associated with severe geometric coronary constraint.Geometric coronary constraints that may affect coronary access after redo TAVR with S3-in-Evolut configurations depend on the implantation depth of both the index Evolut and the simulated S3. However, the hemodynamic significance and clinical impact of these geometric findings require validation through flow studies. Graphical Abstract The alternative text for this image may have been generated using AI.
- Open Access
- 6 January 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (1) , 80-90
Antithrombotic Therapy After Percutaneous Left Atrial Appendage Closure
- 6 January 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (1) , 80-90
Open AccessAntithrombotic Therapy After Percutaneous Left Atrial Appendage Closure
- Open Access
Clinical and hemodynamic outcomes for transcatheter aortic valve implantation in internally stented surgical valve -Comparison of Balloon- and Self-Expandable Valves-
Background: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is indicated in patients undergoing repeat interventions for degenerative aortic valve bioprostheses. Patients with internally stented surgical valves (IS) (Mitroflow and Trifecta) are at a high risk for coronary artery obstruction during the ViV procedure. This study aimed to evaluate the mid-term clinical and hemodynamic outcomes of balloon-expandable valves (BEV) and supra-annular self-expanding valves (SEV) for TAVI within the IS. Methods: Baseline characteristics, hemodynamic parameters, and clinical outcomes of patients who underwent ViV for IS treated with BEV and SEV were retrospectively collected. Outcomes were compared using propensity score matching (PSM). Results: In total, 113 patients were included this analysis. Sixty-three patients (55.8%) underwent BEV, and fifty patients (44.2%) underwent SEV. Overall, 37 pairs were identified after PSM. At 30-day, the clinical and hemodynamic outcomes were similar between the groups. Patients with SEV had better post-procedural mean gradient at 1-year compared with those with BEV (22.7±8.4 mmHg vs 11.7±4.3 mmHg; p<0.001). There was no significant difference between SEV and BEV in the cumulative 2-year composite endpoint, including all-cause of mortality, hospitalization for heart failure, and coronary obstruction (log-rank p=0.489) Conclusions: In patients who underwent ViV for IS, the early- and mid-term clinical outcomes were comparable between BEV and SEV. Meanwhile, the 1-year hemodynamics seemed to be better in patients with SEV than in those with BEV. Clinical Perspective: What is new? Mid-term clinical outcomes, including all-cause mortality, heart failure rehospitalization, and coronary obstruction, were similar between balloon-expandable valve (BEV) and self-expanding valve (SEV) in valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for internally stented surgical valves (IS). SEV group has lower transvalvular gradients at 1-yearfollow-up than BEV group, while the occurrence of coronary obstruction were similar. What are the Clinical Implications? Individualized device selection and improving pre-operative screening for a risk of coronary obstruction, patient-specific anatomical and procedural factors can help the better clinical outcomes.
Open AccessClinical and hemodynamic outcomes for transcatheter aortic valve implantation in internally stented surgical valve -Comparison of Balloon- and Self-Expandable Valves-
Background: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is indicated in patients undergoing repeat interventions for degenerative aortic valve bioprostheses. Patients with internally stented surgical valves (IS) (Mitroflow and Trifecta) are at a high risk for coronary artery obstruction during the ViV procedure. This study aimed to evaluate the mid-term clinical and hemodynamic outcomes of balloon-expandable valves (BEV) and supra-annular self-expanding valves (SEV) for TAVI within the IS. Methods: Baseline characteristics, hemodynamic parameters, and clinical outcomes of patients who underwent ViV for IS treated with BEV and SEV were retrospectively collected. Outcomes were compared using propensity score matching (PSM). Results: In total, 113 patients were included this analysis. Sixty-three patients (55.8%) underwent BEV, and fifty patients (44.2%) underwent SEV. Overall, 37 pairs were identified after PSM. At 30-day, the clinical and hemodynamic outcomes were similar between the groups. Patients with SEV had better post-procedural mean gradient at 1-year compared with those with BEV (22.7±8.4 mmHg vs 11.7±4.3 mmHg; p<0.001). There was no significant difference between SEV and BEV in the cumulative 2-year composite endpoint, including all-cause of mortality, hospitalization for heart failure, and coronary obstruction (log-rank p=0.489) Conclusions: In patients who underwent ViV for IS, the early- and mid-term clinical outcomes were comparable between BEV and SEV. Meanwhile, the 1-year hemodynamics seemed to be better in patients with SEV than in those with BEV. Clinical Perspective: What is new? Mid-term clinical outcomes, including all-cause mortality, heart failure rehospitalization, and coronary obstruction, were similar between balloon-expandable valve (BEV) and self-expanding valve (SEV) in valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for internally stented surgical valves (IS). SEV group has lower transvalvular gradients at 1-yearfollow-up than BEV group, while the occurrence of coronary obstruction were similar. What are the Clinical Implications? Individualized device selection and improving pre-operative screening for a risk of coronary obstruction, patient-specific anatomical and procedural factors can help the better clinical outcomes.
- 23 June 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- p. 1-10
Impact of initial direction of Navitor transcatheter heart valve delivery system on final valve orientation and coronary access
Data on the impact of the initial Navitor transcatheter heart valve (THV) deployment orientation on the final valve orientation in transcatheter aortic valve implantation (TAVI) assessed using post-implantation computed tomography (CT) is scarce. This study aimed to assess the impact of the initial deployment orientation of Navitor THV on the final orientation and neocommissural overlap with the coronary arteries. Additionally, the incidence of commissural misalignment (CMA) of Navitor THV and its impact on coronary access and short-term valve performance were evaluated. Post-TAVI CT was analysed in 77 patients. Severe coronary artery overlap with THV neocommissure was defined as 0°–20° apart. CMA was categorized by angle deviation from the native commissures: aligned (0°–15°), mild (15°–30°), moderate (30°–45°), and severe (45°–60°). The Navitor delivery system was introduced via the femoral artery with the lock button facing the 3, 6, 9, and 12 o’clock positions. Initial Navitor THV deployment orientation had no impact on the incidence of severe coronary artery overlap. Severe CMA was observed in 80.0% at 3 o’clock, 66.7% at 6 o’clock, 53.8% at 9 o’clock, and 42.2% at 12 o’clock position (p = 0.12). Severe CMA was not associated with the success rate of coronary cannulation after TAVI, short-term valve haemodynamics, or the incidence of hypoattenuated leaflet thickening. Initial Navitor THV orientation did not affect coronary artery overlap or CMA. Moreover, CMA of the Navitor THV did not affect coronary access or short-term valve performance. Graphical abstract Impact of initial Navitor transcatheter heart valve deployment orientation on final valve orientation. LCA left coronary artery, LM left main, RCA right coronary artery, THV transcatheter heart valve
- 23 June 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- p. 1-10
Impact of initial direction of Navitor transcatheter heart valve delivery system on final valve orientation and coronary access
Data on the impact of the initial Navitor transcatheter heart valve (THV) deployment orientation on the final valve orientation in transcatheter aortic valve implantation (TAVI) assessed using post-implantation computed tomography (CT) is scarce. This study aimed to assess the impact of the initial deployment orientation of Navitor THV on the final orientation and neocommissural overlap with the coronary arteries. Additionally, the incidence of commissural misalignment (CMA) of Navitor THV and its impact on coronary access and short-term valve performance were evaluated. Post-TAVI CT was analysed in 77 patients. Severe coronary artery overlap with THV neocommissure was defined as 0°–20° apart. CMA was categorized by angle deviation from the native commissures: aligned (0°–15°), mild (15°–30°), moderate (30°–45°), and severe (45°–60°). The Navitor delivery system was introduced via the femoral artery with the lock button facing the 3, 6, 9, and 12 o’clock positions. Initial Navitor THV deployment orientation had no impact on the incidence of severe coronary artery overlap. Severe CMA was observed in 80.0% at 3 o’clock, 66.7% at 6 o’clock, 53.8% at 9 o’clock, and 42.2% at 12 o’clock position (p = 0.12). Severe CMA was not associated with the success rate of coronary cannulation after TAVI, short-term valve haemodynamics, or the incidence of hypoattenuated leaflet thickening. Initial Navitor THV orientation did not affect coronary artery overlap or CMA. Moreover, CMA of the Navitor THV did not affect coronary access or short-term valve performance. Graphical abstract Impact of initial Navitor transcatheter heart valve deployment orientation on final valve orientation. LCA left coronary artery, LM left main, RCA right coronary artery, THV transcatheter heart valve
- 8 January 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (4) , 492-502
Incidence and Prognosis of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement for Bicuspid Aortic Stenosis
- 8 January 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (4) , 492-502
Incidence and Prognosis of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement for Bicuspid Aortic Stenosis
- Open Access
- 28 November 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (12) , ytae659
Successful transcatheter edge-to-edge repair for tricuspid regurgitation in a patient with a double-inlet left ventricle and discordant connections of the great arteries: a case report
Background: In patients with adult congenital heart disease (ACHD), significant atrioventricular valve regurgitation is an important risk factor for poor outcomes, such as heart failure. However, in many cases, transcatheter intervention may reduce the risk profile to avoid a high surgical risk. Case summary: A 44-year-old man with complex ACHD in the form of a double-inlet left ventricle, congenitally corrected transposition of the great arteries, pulmonary atresia, atrial septal defect, and patent ductus arteriosus was referred for the treatment of severe tricuspid regurgitation. He received an aortopulmonary shunt and a left-sided modified Blalock-Taussig shunt during childhood. Because of the patient’s high surgical risk due to seroma formation around the two shunts and intra-mediastinal collateral vessels, the heart team opted for transcatheter edge-to-edge repair (TEER) using a MitraClip (Abbott Vascular, Santa Clara, CA, USA). Tricuspid TEER was successfully performed using the MitraClip G4 system. The postoperative course was uneventful, with significant improvements in the New York Heart Association functional class. Discussion: Our case demonstrates that tricuspid TEER can be an alternative option for patients with complex ACHD who are at high risk for conventional surgeries; however, careful assessment with multimodality imaging and a heart team approach, including a cardiologist, ACHD specialist, cardiac surgeon, anthologist, and intensivist, should be considered.
- 28 November 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (12) , ytae659
Open AccessSuccessful transcatheter edge-to-edge repair for tricuspid regurgitation in a patient with a double-inlet left ventricle and discordant connections of the great arteries: a case report
Background: In patients with adult congenital heart disease (ACHD), significant atrioventricular valve regurgitation is an important risk factor for poor outcomes, such as heart failure. However, in many cases, transcatheter intervention may reduce the risk profile to avoid a high surgical risk. Case summary: A 44-year-old man with complex ACHD in the form of a double-inlet left ventricle, congenitally corrected transposition of the great arteries, pulmonary atresia, atrial septal defect, and patent ductus arteriosus was referred for the treatment of severe tricuspid regurgitation. He received an aortopulmonary shunt and a left-sided modified Blalock-Taussig shunt during childhood. Because of the patient’s high surgical risk due to seroma formation around the two shunts and intra-mediastinal collateral vessels, the heart team opted for transcatheter edge-to-edge repair (TEER) using a MitraClip (Abbott Vascular, Santa Clara, CA, USA). Tricuspid TEER was successfully performed using the MitraClip G4 system. The postoperative course was uneventful, with significant improvements in the New York Heart Association functional class. Discussion: Our case demonstrates that tricuspid TEER can be an alternative option for patients with complex ACHD who are at high risk for conventional surgeries; however, careful assessment with multimodality imaging and a heart team approach, including a cardiologist, ACHD specialist, cardiac surgeon, anthologist, and intensivist, should be considered.
- 10 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (1) , 107-117
Difference in cardiac response after transcatheter aortic valve implantation according to flow and gradient pattern
Aims: In patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS), data on the differences in subsequent cardiac structure and function among stratified groups with flow gradient patterns through the aortic valve are insufficient. Methods and results: In this large multicenter study, 4523 patients undergoing TAVI for severe AS between 2013 and 2019 were divided into three groups according to the following criteria: (i) high-gradient AS (HG-AS) [mean pressure gradient (MPG) ≥ 40 mmHg], (ii) classical low-flow low-gradient AS (cLFLG-AS) [MPG < 40 mmHg, left ventricular (LV) ejection fraction (LVEF) <50%], and (iii) paradoxical low-flow low-gradient AS (pLFLG-AS) [MPG < 40 mmHg, LVEF ≥ 50% but stroke volume index (SVi) <35 mL/m2]. Echocardiography was performed at baseline, post-procedure, and 1 year post-TAVI. 3697, 507, and 319 patients had HG-AS, cLFLG-AS, and pLFLG-AS, respectively. After adjusting for clinical factors, cLFLG-AS and pLFLG-AS had an ∼1.5-fold higher 2-year all-cause mortality compared with HG-AS. During 1 year following TAVI, compared with HG-AS, cLFLG-AS showed greater reduction of LV systolic diameter (LVDs) and LV diastolic diameter (LVDd) and greater increase of LVEF (P < 0.001 for all), and changes in LV mass index (LVMi) and SVi were comparable (P = 0.915 and P = 0.821, respectively). However, pLFLG-AS demonstrated less reduction of LVDs and LVDd (P = 0.039 and P = 0.001, respectively), less improvement of LVEF and LVMi (P = 0.045 and P < 0.001, respectively), and comparable change in SVi (P = 0.364). Conclusion: During 1 year post-TAVI, compared with HG-AS, cLFLG-AS achieves smaller LV diameters, greater increase in LVEF, and comparable regression of LVMi, whereas pLFLG-AS does not.
- 10 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (1) , 107-117
Difference in cardiac response after transcatheter aortic valve implantation according to flow and gradient pattern
Aims: In patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS), data on the differences in subsequent cardiac structure and function among stratified groups with flow gradient patterns through the aortic valve are insufficient. Methods and results: In this large multicenter study, 4523 patients undergoing TAVI for severe AS between 2013 and 2019 were divided into three groups according to the following criteria: (i) high-gradient AS (HG-AS) [mean pressure gradient (MPG) ≥ 40 mmHg], (ii) classical low-flow low-gradient AS (cLFLG-AS) [MPG < 40 mmHg, left ventricular (LV) ejection fraction (LVEF) <50%], and (iii) paradoxical low-flow low-gradient AS (pLFLG-AS) [MPG < 40 mmHg, LVEF ≥ 50% but stroke volume index (SVi) <35 mL/m2]. Echocardiography was performed at baseline, post-procedure, and 1 year post-TAVI. 3697, 507, and 319 patients had HG-AS, cLFLG-AS, and pLFLG-AS, respectively. After adjusting for clinical factors, cLFLG-AS and pLFLG-AS had an ∼1.5-fold higher 2-year all-cause mortality compared with HG-AS. During 1 year following TAVI, compared with HG-AS, cLFLG-AS showed greater reduction of LV systolic diameter (LVDs) and LV diastolic diameter (LVDd) and greater increase of LVEF (P < 0.001 for all), and changes in LV mass index (LVMi) and SVi were comparable (P = 0.915 and P = 0.821, respectively). However, pLFLG-AS demonstrated less reduction of LVDs and LVDd (P = 0.039 and P = 0.001, respectively), less improvement of LVEF and LVMi (P = 0.045 and P < 0.001, respectively), and comparable change in SVi (P = 0.364). Conclusion: During 1 year post-TAVI, compared with HG-AS, cLFLG-AS achieves smaller LV diameters, greater increase in LVEF, and comparable regression of LVMi, whereas pLFLG-AS does not.
- Open Access
- 2 August 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (8) , ytae425
Scleroderma myocarditis with severe secondary mitral regurgitation successfully treated with transcatheter edge-to-edge repair: a case report
Background: Systemic sclerosis presents with a variety of cardiac manifestations, while myocarditis is usually a rare finding. Furthermore, there are no reports on the use of mitral transcatheter edge-to-edge repair (M-TEER) for the treatment of severe ventricular functional mitral regurgitation (vFMR) secondary to scleroderma myocarditis. Case summary: A-79-year-old male was admitted to our hospital because of fever and fatigue. His physical examination revealed thickening of the fingertips’ skin, Raynaud phenomenon, and mild pedal oedema. Positive anti-centromere antibodies indicated a diagnosis of a limited cutaneous systemic sclerosis. He presented with symptoms of heart failure, and moderate to severe lymphocytic infiltration was evident in his endomyocardial biopsy. He responded well to medical therapy and was discharged. However, one month after hospital discharge, he was readmitted to our institution because of worsening heart failure. Transthoracic echocardiography showed a decrease in left ventricular systolic function and progression of left ventricular remodelling, which caused severe vFMR. Endomyocardial biopsy revealed decreased lymphocytic infiltration and mild myocardial interstitial fibrosis, indicative of scleroderma myocarditis. As he was unable to be weaned off inotropes, we performed M-TEER for severe vFMR, which led to a significant reduction in MR volume and improvement of heart failure symptoms. A week after procedure, immunosuppressive therapy was initiated and the patient was discharged home in stable condition. Discussion: Scleroderma myocarditis may manifest as heart failure with reduced ejection fraction with severe vFMR. Mitral transcatheter edge-to-edge repair for severe vFMR in the context of myocarditis can be one of the therapeutic options for haemodynamic stabilization.
- 2 August 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (8) , ytae425
Open AccessScleroderma myocarditis with severe secondary mitral regurgitation successfully treated with transcatheter edge-to-edge repair: a case report
Background: Systemic sclerosis presents with a variety of cardiac manifestations, while myocarditis is usually a rare finding. Furthermore, there are no reports on the use of mitral transcatheter edge-to-edge repair (M-TEER) for the treatment of severe ventricular functional mitral regurgitation (vFMR) secondary to scleroderma myocarditis. Case summary: A-79-year-old male was admitted to our hospital because of fever and fatigue. His physical examination revealed thickening of the fingertips’ skin, Raynaud phenomenon, and mild pedal oedema. Positive anti-centromere antibodies indicated a diagnosis of a limited cutaneous systemic sclerosis. He presented with symptoms of heart failure, and moderate to severe lymphocytic infiltration was evident in his endomyocardial biopsy. He responded well to medical therapy and was discharged. However, one month after hospital discharge, he was readmitted to our institution because of worsening heart failure. Transthoracic echocardiography showed a decrease in left ventricular systolic function and progression of left ventricular remodelling, which caused severe vFMR. Endomyocardial biopsy revealed decreased lymphocytic infiltration and mild myocardial interstitial fibrosis, indicative of scleroderma myocarditis. As he was unable to be weaned off inotropes, we performed M-TEER for severe vFMR, which led to a significant reduction in MR volume and improvement of heart failure symptoms. A week after procedure, immunosuppressive therapy was initiated and the patient was discharged home in stable condition. Discussion: Scleroderma myocarditis may manifest as heart failure with reduced ejection fraction with severe vFMR. Mitral transcatheter edge-to-edge repair for severe vFMR in the context of myocarditis can be one of the therapeutic options for haemodynamic stabilization.
- Open Access
- 25 March 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (4) , 462-471
Long-Term Assessment of Survival After Transcatheter Aortic Valve Implantation ― Insights From the International Transcatheter Aortic Valve Implantation Registry ―
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis (AS), but despite estimates of life expectancy after TAVI being essential in heart team discussion, these data are scarce. Therefore, the current study sought to assess long-term survival and its trends in relation to chronological age, surgical risk, and treatment period.Methods and Results: We included 2,414 consecutive patients who underwent TAVI for severe symptomatic AS between 2008 and 2021 at 2 international centers. For the analysis, long-term survival was evaluated according to age, surgical risk, and treatment period categorized into 3 groups, respectively. The longest follow-up was 13.5 years. Overall survival was 67.6% at 5 years and 26.9% at 10 years. Younger patients, lower surgical risk, and later treatment period showed better survival (log-rank P<0.001, respectively). In the multivariate analysis, age <75years, lower surgical risk, and later time period were significantly associated with better survival. The incidence of paravalvular leakage ≥moderate, red blood cell transfusion, and acute kidney injury were independently associated with increasing risk of 5-year death.Conclusions: In a real-world registry, survival was substantial following TAVI, especially in younger and lower surgical-risk patients, with improving outcomes over time. This should be considered in heart team discussions of life-long management for AS patients after TAVI.
- 25 March 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (4) , 462-471
Open AccessLong-Term Assessment of Survival After Transcatheter Aortic Valve Implantation ― Insights From the International Transcatheter Aortic Valve Implantation Registry ―
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis (AS), but despite estimates of life expectancy after TAVI being essential in heart team discussion, these data are scarce. Therefore, the current study sought to assess long-term survival and its trends in relation to chronological age, surgical risk, and treatment period.Methods and Results: We included 2,414 consecutive patients who underwent TAVI for severe symptomatic AS between 2008 and 2021 at 2 international centers. For the analysis, long-term survival was evaluated according to age, surgical risk, and treatment period categorized into 3 groups, respectively. The longest follow-up was 13.5 years. Overall survival was 67.6% at 5 years and 26.9% at 10 years. Younger patients, lower surgical risk, and later treatment period showed better survival (log-rank P<0.001, respectively). In the multivariate analysis, age <75years, lower surgical risk, and later time period were significantly associated with better survival. The incidence of paravalvular leakage ≥moderate, red blood cell transfusion, and acute kidney injury were independently associated with increasing risk of 5-year death.Conclusions: In a real-world registry, survival was substantial following TAVI, especially in younger and lower surgical-risk patients, with improving outcomes over time. This should be considered in heart team discussions of life-long management for AS patients after TAVI.
- 6 March 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (6) , 810-813
Late Sinus Sequestration After TAVR-in-TAVR Rescued by Coronary Artery Bypass Grafting
- 6 March 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (6) , 810-813
Late Sinus Sequestration After TAVR-in-TAVR Rescued by Coronary Artery Bypass Grafting